Home » Stocks & Shares » AstraZeneca heads south after disappointing MYSTIC trial results

AstraZeneca heads south after disappointing MYSTIC trial results

Tsveta van Son
  • November 16th 2018, 10:40
  • Last Updated: October 21st 2019, 15:12

Shares in AstraZeneca (LON:AZN) have lost ground in London in today’s session, as the company posted disappointing results from its key MYSTIC study. The setback comes after the highly-awaited oncology trial delivered disappointing initial results last year.

As of 10:25 GMT, AstraZeneca’s share price had given up 2.28 percent to 6,173.00p. The shares are underperforming the broader UK market, with the benchmark FTSE 100 index having inched marginally into positive territory and currently standing 0.04 percent higher at 7,041.04 points.

Disappointing MYSTIC trial results

AstraZeneca announced in a statement this morning that the final overall survival results for its late-stage MYSTIC trial showed that the combination of its oncology drug Imfinzi and tremelimumab, a type of antibody treatment, did not meet the primary endpoints of improving overall survival compared to standard-of-care  chemotherapy in previously-untreated patients with Stage IV (metastatic) non-small cell lung cancer.

“We are disappointed that these results missed statistical significance,” the group’s chief medical officer Sean Bohen commented in the statement, adding, however, that the company remained ‘confident’ in Imfinzi as ‘the cornerstone’ of its immuno-oncology programme and continued to  evaluate its potential in ongoing non-small cell lung cancer trials, “including Imfinzi and Imfinzi plus tremelimumab in combination with chemotherapy”. The drug has already been approved for Stage III lung cancer in more than 40 countries.

The results mark a setback for AstraZeneca which has bet on oncology as one of its key therapy areas to propel sales growth.

Analysts on blue-chip pharmco

JPMorgan Chase & Co, which sees AstraZeneca as a ‘buy,’ set a price target of 6,900p on the shares today. According to MarketBeat, the Anglo-Swedish drugmaker currently has a consensus ‘buy’ rating and an average price target of 5,905.53p.

As of 10:41 GMT, Friday, 16 November, AstraZeneca plc share price is 6,146.00p.

About the author

Tsveta van Son
Tsveta van Son is part of Invezz’s journalist team. She has a BA degree in European Studies and a MA degree in Nordic Studies from Sofia University and has also attended the University of Iceland. While she covers a variety of investment news, she is particularly interested in developments in the field of renewable energy.

Leave a Reply

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.